Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Huaren Pharmaceutical CoSZSE:300110 +0.35%55 Piotroski F-Score is 6 as of Aug. 26, 2026, which is at its 10-year median of 6.00. GuruFocus rates SZSE:300110 with a GF Score™ of 55/100 and a GF Value™ of ¥3.13 (Fairly Valued). The stock has 8 warning signs investors should review. Among 983 Drug Manufacturers companies, Huaren Pharmaceutical Co ranks better than 78.43% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Huaren Pharmaceutical Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Huaren Pharmaceutical Co's Piotroski F-Score or its related term are showing as below:
SZSE:300110'
s Piotroski F-Score Range Over the Past 10 Years
Min: 3 Med: 6 Max: 9
Current: 6
During the past 13 years, the highest Piotroski F-Score of Huaren Pharmaceutical Co was 9. The lowest was 3. And the median was 6.
Huaren Pharmaceutical Co (SZSE:300110) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Huaren Pharmaceutical Co Piotroski F-Score Related Terms
Huaren Pharmaceutical Co Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Huaren Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Huaren Pharmaceutical Co Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Huaren Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Huaren Pharmaceutical Co's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Huaren Pharmaceutical Co's current Net Income (TTM) was -463.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Huaren Pharmaceutical Co's current Cash Flow from Operations (TTM) was 308.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Huaren Pharmaceutical Co's return on assets of this year was -0.13418782. Huaren Pharmaceutical Co's return on assets of last year was -0.28057708.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Huaren Pharmaceutical Co's gearing of this year was 0.14758395. Huaren Pharmaceutical Co's gearing of last year was 0.09038258.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Huaren Pharmaceutical Co's current ratio of this year was 0.82010827. Huaren Pharmaceutical Co's current ratio of last year was 0.72032995.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Huaren Pharmaceutical Co's number of shares in issue this year was 1182.119. Huaren Pharmaceutical Co's number of shares in issue last year was 1178.562.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Huaren Pharmaceutical Co's gross margin of this year was 0.36330441. Huaren Pharmaceutical Co's gross margin of last year was 0.33242395.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Huaren Pharmaceutical Co's asset turnover of this year was 0.38489388. Huaren Pharmaceutical Co's asset turnover of last year was 0.24991697.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
1
+
1
+
1
+
0
+
1
+
0
+
1
+
1
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Huaren Pharmaceutical Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.
Huaren Pharmaceutical Co (SZSE:300110) has a Piotroski F-Score of 6 as of Aug. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Huaren Pharmaceutical Co and its competitors. This is near median its historical median of 6.00. Over the past decade, Huaren Pharmaceutical Co's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, Huaren Pharmaceutical Co ranks #212 out of 983 companies in the Drug Manufacturers industry, placing it in the top 21.6%.
Is Huaren Pharmaceutical Co's Piotroski F-Score too high?
Huaren Pharmaceutical Co's current Piotroski F-Score of 6 is near median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Huaren Pharmaceutical Co's value of 6 is 20% above this industry median. Based on the distribution chart, Huaren Pharmaceutical Co ranks #212 out of 983 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Huaren Pharmaceutical Co has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Huaren Pharmaceutical Co's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Huaren Pharmaceutical Co ranks #212 out of 983 companies for Piotroski F-Score. This places Huaren Pharmaceutical Co in the top 22% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Huaren Pharmaceutical Co's value of 6 is 20% above this benchmark. Historically, Huaren Pharmaceutical Co's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Huaren Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Huaren Pharmaceutical Co's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Huaren Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Huaren Pharmaceutical Co's current Piotroski F-Score is 6, which is near median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Huaren Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Huaren Pharmaceutical Co (SZSE:300110) is currently considered Fairly Valued. The stock's GF Value™ is ¥3.13, compared to a current price of ¥2.90 — trading 7.3% below its estimated fair value. The current Piotroski F-Score is 6, which is near median its 10-year median of 6.00 and 20% above the Drug Manufacturers industry median of 5.00. Huaren Pharmaceutical Co's overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Huaren Pharmaceutical Co (SZSE:300110), the current Piotroski F-Score is 6 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Huaren Pharmaceutical Co (SZSE:300110) Overvalued in 2026?
Based on GuruFocus' analysis, Huaren Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥2.90 is trading 7.3% below its estimated GF Value™ of ¥3.13.
GuruFocus considers Huaren Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SZSE:300110:
Piotroski F-Score: 6 (near median its 10-year median of 6.00)
GF Value™: ¥3.13 vs. price of ¥2.90 (7.3% below fair value)
Industry Position: 20% above the Drug Manufacturers median (#212 of 983)
No single metric tells the full story. See the SZSE:300110 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Huaren Pharmaceutical Co Ltd is a China-based company engaged in the manufacture, and sale of non-polyvinyl chloride and Non-PVC large capacity preparations. Its categories of products include conventional infusion, therapy infusion, and nutrition infusion. The company distributes its products in domestic market, with Northeast China as its main market.
55GF Score
Get the complete analysis for SZSE:300110
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:300110 has been successfully added to your 
